logo
Share SHARE
FONT-SIZE Plus   Neg

Boston Scientific Begins Trial To Study Neurostimulation For Migraine Treatment

Boston Scientific Corporation(BSX), a maker of medical devices, Friday said it launched a clinical trial, OPTIMISE, to find out if occipital nerve stimulation or ONS using the Precision System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications. The multi-center, randomized, placebo-controlled study is expected to be used to support various regulatory approvals of this novel therapy for chronic migraine.

With ONS, a small programmable implanted device sends electrical impulses to the greater occipital nerve, which runs from the top of the spinal cord to the base of the scalp. The Precision System for chronic migraine is investigational and is currently available as an approved treatment in the U.S., Canada, Europe and Australia as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome and intractable low back pain and leg pain.

"We believe that the Boston Scientific neurostimulation therapy for migraine has enormous potential to help migraine sufferers worldwide..." said Maulik Nanavaty, president, Neuromodulation, Boston Scientific.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
We urge Investors to take advantage of the weakness in the shares of Applied Optoelectronics, Inc. (AAOI), as we believe the stock has at least 15% upside from current levels. The stock is down along with many of the stocks in the Fiber optical component universe with an exposure to China. Nestle SA's shares were gaining around 4 percent in Zurich trading after billionaire activist investor Daniel Loeb's hedge fund Third Point LLC bought a $3.5 billion stake in the Swiss food giant. The acquisition of about 1.25% stake in Nestle would put pressure on the company to find ways to accelerate growth. We believe this stock is well-positioned for at least 15% upside from current $23 levels. The stock featured on our premium product Short-Term Investor on April 25 at an opening price of $19.5, and on June 9 touched an intra-day high of $29.73, returning a gain of 52.4% to investors. It is now at an attractive price point again.
comments powered by Disqus
Follow RTT